DGAP-News

WILEX AG: WILEX signs antibody license agreement with Telix Pharmaceuticals Limited

DGAP-News: WILEX AG / Key word(s): Alliance WILEX AG: WILEX signs antibody license agreement with Telix Pharmaceuticals Limited 16.01.2017 / 09:29 The issuer is solely responsible for the content of this announcement. PRESS RELEASE

WILEX signs antibody license agreement with Telix Pharmaceuticals Limited

- Telix receives exclusive worldwide rights for the development and commercialization of diagnostic agent REDECTANE(R) (INN: 124I-Girentuximab)

- Telix also receives development rights to Girentuximab for use with therapeutic radionuclides, such as 177Lu (Lutetium)

- Telix is responsible for the manufacturing of Girentuximab for both diagnostic and therapeutic applications

- WILEX to receive upfront payment plus potential clinical and regulatory milestone payments and attractive royalties

Munich, Germany / Melbourne, Australia, 16 January 2017 - WILEX AG (ISIN DE000A11QVV0 / WL6 / FSE) and Australian biopharmaceutical company Telix Pharmaceuticals Limited ("Telix"), today announced that they have concluded a worldwide license agreement for the development and commercialization of the imaging agent REDECTANE(R), a radiolabeled form of the monoclonal antibody Girentuximab. Girentuximab binds to Carbonic Anhydrase-9 (CAIX), an antigen highly expressed on clear cell renal cell carcinoma (ccRCC) cells. Targeting and accumulation of radiolabeled-antibodies in tumor tissue can be visualized by molecular imaging with Positron Emission Tomography (PET) and has significant diagnostic and staging value in the management of renal (kidney) cancer. WILEX has successfully completed a first Phase III trial with REDECTANE(R) in ccRCC.

WILEX has granted Telix the worldwide licensing rights to further develop and commercialize the REDECTANE(R) molecular imaging program. Under the agreement, Telix will, as a first step, invest in an improved manufacturing process for the antibody. Under the terms of the agreement, WILEX is eligible to receive up-front and milestone payments totaling USD 3.7 million. In addition, WILEX is eligible to receive significant royalties on global net sales of REDECTANE(R), commensurate with a Phase III asset. Telix will be responsible for all development costs, as well as manufacturing and commercialization costs.